Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Army Seeks Development of Bioscavenger Prophylactics for Chemical Nerve Agents

by Global Biodefense Staff
April 9, 2012

The deadline is quickly approaching on an Army sponsored Request for Proposals (RFP) to develop nerve agent prophylactics.

The overall goal of the project is to select, develop, and manufacture an FDA-approved drug to increase survival and decrease incapacitation such that forces can maintain operational effectiveness within a contaminated area following nerve agent exposure, irrespective of nerve agent type.

The project, managed by U.S. Army Contracting Command Aberdeen Proving Grounds (ACC-APG) Natick Division, seeks to deliver a countermeasure which is safe, quick acting, free from performance-decrementing side effects, compatible with current military CBRN countermeasures, and usable in contemporary operational environments.

The proposed schedule calling for actual delivery of the Bioscavenger (BSCAV)/Nerve Agent Prophylactic is anticipated within 6 years after contract award, but all proposed delivery schedules will be evaluated.

Full details are under Solicitation Number W911QY-12-R-0014. The current response deadline is April 16, 2012.

Tags: BioscavengersRequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC